![]() ![]() The Exogen device was found to be no more effective at healing fractures than a sham treatment. Bioventus said the funding was pulled to prevent inconvenience to patients and to reduce their exposure to X-rays. “They didn’t see an obvious reason to continue to support a study that would not be supportive of their product,” Busse said. Upon learning that the treatment had no apparent benefits, the company yanked funding for the trial, Busse said. In 2012, the year the last patients were enrolled, Bioventus conducted an unplanned early review of the data. ĥ makeshift - and ingenious - ways to improve medical devices Some of those studies were coauthored by the inventor of the device. Earlier trials showing some benefit were methodologically suspect, said Jason Busse, a researcher at McMaster University in Hamilton, Ontario. And it raised questions about how rigorously the device was vetted before going on the market. It was by far the largest randomized, controlled clinical study of the technology. #SMITH AND NEPHHEW EXOGEN BONE HEALING SYSTEM FULL#(Their healing was assessed by X-rays and by how quickly they could bear full weight and return to normal activities.) It found that patients treated with “low-intensity pulsed ultrasound” healed at the same rate as those given a sham treatment. The trial at sites in Canada and the United States involved 501 patients who had surgical repair of fractures of the tibia - the larger of two leg bones between the knee and ankle. Exclusive analysis of biotech, pharma, and the life sciences Learn MoreĪn ultrasound device meant to speed healing of bone fractures is ineffective, according to a new clinical trial - though it has been on the market for 22 years and has rung up hundreds of millions of dollars in sales. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |